The level of PrP^Sc was reduced only in the grey matter of the thalamus of RML-infected CD-1 mice treated with AAV2-PrP-shRNA.

<p><b>a</b>. CD-1 mice were inoculated with RML and i) untreated (n = 15), ii) infused with AAV2-PrP-shRNA at 50 dpi (n = 12) or iii) infused with AAV2-PrP-shRNA in combination with GSI/Qa treatment for 28 days at 50 dpi (n = 12). Both inoculation and infusion was into the thalamus. Scrapie-sick mice were euthanized and the brain samples were collected for flash-frozen, sectioned (10 µm thickness) and analyzed by histoblot with PK digestion. Samples shown in the figure are from mice of each group died of prion disease around 140 dpi. <b>b</b>. The level of PrP^Sc was measured by Western blot analysis. Flash frozen brains were micro-dissected into three regions; the cortex, thalamus and brainstem. 5 µg of protein lysates were digested with PK and run in a SDS PAGE gel (1: untreated control, 2: RML-infected mice treated with AAV2-PrP-shRNA at 50 dpi, 3: RML-infected mice treated with AAV2-PrP-shRNA with a combination of GSI and Qa treatment for 28 days of oral administration at 50 dpi). Samples shown in the figure are mice of each group died of prion disease around 118–136 dpi.